First Time Loading...

Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73%
Updated: May 7, 2024

Amryt Pharma Holdings Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amryt Pharma Holdings Ltd
Operating Income Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Amryt Pharma Holdings Ltd
LSE:AMYT
Operating Income
-$45.4m
CAGR 3-Years
-40%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Operating Income
£7.3B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
1%
AstraZeneca PLC
LSE:AZN
Operating Income
$8.6B
CAGR 3-Years
27%
CAGR 5-Years
14%
CAGR 10-Years
11%
Indivior PLC
LSE:INDV
Operating Income
$257m
CAGR 3-Years
20%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Operating Income
$622m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
6%
Dechra Pharmaceuticals PLC
LSE:DPH
Operating Income
£24.9m
CAGR 3-Years
-25%
CAGR 5-Years
-11%
CAGR 10-Years
3%

See Also

What is Amryt Pharma Holdings Ltd's Operating Income?
Operating Income
-45.4m USD

Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Operating Income amounts to -45.4m USD.

What is Amryt Pharma Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-94%

Over the last year, the Operating Income growth was -39%. The average annual Operating Income growth rates for Amryt Pharma Holdings Ltd have been -40% over the past three years , -94% over the past five years .